XML 42 R27.htm IDEA: XBRL DOCUMENT
v3.22.4

Segment Reporting | 12 Months Ended
--- | ---
Dec. 31, 2022
Segment Reporting [Abstract] |
Segment Reporting | SEGMENT REPORTING We operate primarily through three business segments: Companion Animal Group (“CAG”), Water quality products (“Water”), and Livestock, Poultry and Dairy (“LPD”). CAG provides products and services for veterinarians and the biomedical research community, primarily related to diagnostics and information management. Water provides innovative testing solutions for the detection and quantification of various microbiological parameters in water. LPD provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk. Our Other operating segment combines and presents our human medical diagnostic business (“OPTI Medical”) with our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments. OPTI Medical develops, manufactures, and distributes human medical diagnostic products and provides human medical diagnostic services. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include: CAG, Water, LPD, and Other. Assets are not allocated to segments for internal reporting purposes. Intersegment revenues, which are not included in the table below, were not material for the years ended December 31, 2022, 2021, and 2020. The following is a summary of segment performance:
(in thousands) |  | For the Years Ended December 31,
|  | CAG |  | Water |  | LPD |  | Other |  | Consolidated Total
2022 |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 3,058,793 |  |  | $ | 155,720 |  |  | $ | 122,607 |  |  | $ | 30,204 |  |  | $ | 3,367,324 |
Income from operations |  | $ | 800,949 |  |  | $ | 72,519 |  |  | $ | 19,809 |  |  | $ | 5,488 |  |  | $ | 898,765 |
Interest expense, net |  |  |  |  |  |  |  |  |  | (38,793) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  | 859,972 |
Provision for income taxes |  |  |  |  |  |  |  |  |  | 180,883 |
Net income |  |  |  |  |  |  |  |  |  | 679,089 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  | — |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  | $ | 679,089 |
Depreciation and amortization |  | $ | 101,254 |  |  | $ | 3,020 |  |  | $ | 3,797 |  |  | $ | 3,829 |  |  | $ | 111,900 |
2021 |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 2,889,960 |  |  | $ | 146,505 |  |  | $ | 135,887 |  |  | $ | 43,008 |  |  | $ | 3,215,360 |
Income from operations |  | $ | 824,022 |  |  | $ | 65,444 |  |  | $ | 28,636 |  |  | $ | 13,926 |  |  | $ | 932,028 |
Interest expense, net |  |  |  |  |  |  |  |  |  | (29,374) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  | 902,654 |
Provision for income taxes |  |  |  |  |  |  |  |  |  | 157,810 |
Net income |  |  |  |  |  |  |  |  |  | 744,844 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  | (1) |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  | $ | 744,845 |
Depreciation and amortization |  | $ | 94,202 |  |  | $ | 2,709 |  |  | $ | 3,908 |  |  | $ | 3,777 |  |  | $ | 104,596 |
2020 |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 2,385,765 |  |  | $ | 128,625 |  |  | $ | 145,845 |  |  | $ | 46,420 |  |  | $ | 2,706,655 |
Income from operations |  | $ | 574,887 |  |  | $ | 58,867 |  |  | $ | 40,008 |  |  | $ | 20,762 |  |  | $ | 694,524 |
Interest expense, net |  |  |  |  |  |  |  |  |  | (32,539) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  | 661,985 |
Provision for income taxes |  |  |  |  |  |  |  |  |  | 79,854 |
Net income |  |  |  |  |  |  |  |  |  | 582,131 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  | 355 |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  | $ | 581,776 |
Depreciation and amortization |  | $ | 84,697 |  |  | $ | 2,630 |  |  | $ | 4,070 |  |  | $ | 4,601 |  |  | $ | 95,998 |
Refer to “Note 3. Revenue Recognition” for a summary of disaggregated revenue by reportable segment and by major product and service category for the years ended December 31, 2022, 2021, and 2020. Net long-lived assets, consisting of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net long-lived assets by principal geographic areas were as follows:
(in thousands) |  |  |  |
|  | December 31, 2022 |  | December 31, 2021
Americas |  |  |  |
United States |  | $ | 486,690 |  |  | $ | 436,003 |
Brazil |  | 25,949 |  |  | 17,043 |
Canada |  | 7,407 |  |  | 7,003 |
|  | 520,046 |  |  | 460,049 |
Europe, the Middle East and Africa |  |  |  |
Germany |  | 55,726 |  |  | 60,451 |
United Kingdom |  | 10,710 |  |  | 9,828 |
Netherlands |  | 11,975 |  |  | 19,405 |
France |  | 1,507 |  |  | 1,884 |
Switzerland |  | 13,445 |  |  | 3,545 |
Other |  | 3,054 |  |  | 3,821 |
|  | 96,417 |  |  | 98,934 |
Asia Pacific Region |  |  |  |
Japan |  | 5,111 |  |  | 5,845 |
Australia |  | 20,243 |  |  | 14,584 |
Other |  | 7,657 |  |  | 8,255 |
|  | 33,011 |  |  | 28,684 |
Total |  | $ | 649,474 |  |  | $ | 587,667 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration